1. Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J. 2006;12:3.
2. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol. 2003;14:1792.
3. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 2002;70:329.
4. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10:588–96.
5. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non Hodgkin lymphoma: preliminary analysis of the GAUSS study. Paper presented at: 53rd ASH annual meeting and exposition, December 10–13, 2011, San Diego, CA, USA.